CliffBio
biologic

Trodelvy

sacituzumab govitecan-hziy

Loss of exclusivity—loss of exclusivity
CompanyGilead Sciences →See this company's full patent-cliff portfolio

Drug detail

Brand nameTrodelvy
Active ingredientsacituzumab govitecan-hziy
Strength180MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Gilead Sciences

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.